Moreover, the molecular pathways of chronic inflammation, which lead to insulin resistance, a decrease in insulin receptor levels, and apoptosis induction in pancreatic cells, must also be targeted to develop innovative therapeutic approaches for T2DM treatment. This evidence concerns the gene INSR and Insulin resistance.